CA-CEPTON-TECHNOLOGIES
11.10.2021 15:02:06 CEST | Business Wire | Press release
Cepton Technologies, Inc., an innovative provider of smart lidar solutions , announced today its membership in the Qualcomm® Smart Cities Accelerator Program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005191/en/
The Qualcomm Smart Cities Accelerator Program brings technologies and companies together to collaborate, innovate, and accelerate the rollout of smart cities and smart connected spaces globally. Cepton believes its presence in this ecosystem aligns with Qualcomm Technologies, Inc.’s vision of bringing efficient, safe, and advanced technology to fast-growing urban environments. With its membership, Cepton aims to advance the use of lidar-based solutions with ecosystem members of the Qualcomm Smart Cities Accelerator Program across smart cities and smart connected spaces.
Through the Qualcomm® IoT Services Suite, Cepton and one of its key partners in smart spaces, The Indoor Lab, plan to collaborate with Qualcomm Technologies in offering Smart Venues as a Service , utilizing a lidar-based crowd analytics system which adheres to the privacy concerns and optimizes the utilization of spaces.
With its high-accuracy, 3D perception capabilities and 24/7 availability , lidar can enable a wide range of applications to help build safer, smarter, and better-connected environments. Thanks to their anonymized data, lidars maximize protection of people’s privacy as they collect useful information to help drive intelligent decisions in smart cities and smart spaces. Cepton has been working with global partners to enable the transformation of transportation infrastructure, public venues and large commercial facilities using smart lidar solutions. For example, Cepton’s partnership with The Indoor Lab deployed a lidar-based crowd analytics solution as a pilot project at an Orlando International Airport terminal in 2020 to offer anonymous foot fall tracking, helping maintenance crews in targeted cleaning and travelers in avoiding crowded areas.
“We are proud to join Qualcomm Technologies’ network of technology innovators through the Qualcomm Smart Cities Accelerator Program as we work to help advance the future of smart infrastructure with our lidar technologies,” said Dr. Jun Pei, CEO of Cepton. “To date, our technology has been successfully used to enable real-time traffic and pedestrian monitoring at road and rail intersections , free-flow electronic tolling systems , critical infrastructure security , and crowd analytics . By joining the Qualcomm Smart Cities Accelerator Program ecosystem, we look forward to making our technologies more accessible on a global scale.”
“Our partnership with Cepton has been invaluable to establish The Indoor Lab as a market leader for lidar-based analytics,” said Patrick Blattner, Co-Founder and Chief Product Officer of The Indoor Lab . “Last week at the 3rd Annual Qualcomm Smart Cities Accelerate Event, we were proud to showcase our solution and its wide variety of applications to the global Qualcomm Smart Cities Accelerator Program ecosystem.”
"We are pleased to welcome Cepton as a member of our cutting-edge Qualcomm Smart Cities Accelerator Program. We look forward to working together to bring cutting-edge smart lidar solutions and applications to a variety of urban environments and collaborating to offer Smart Venues as a Service through the Qualcomm® IoT Services Suite," said Sanjeet Pandit, Senior Director, Business Development, and Global Head of Smart Cities, Qualcomm Technologies, Inc.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm IoT Services Suite is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
